CSBT.F logo

Kuros Biosciences OTCPK:CSBT.F Stock Report

Last Price

US$22.57

Market Cap

US$844.7m

7D

0%

1Y

431.1%

Updated

24 Dec, 2024

Data

Company Financials

Kuros Biosciences AG

OTCPK:CSBT.F Stock Report

Market Cap: US$844.7m

CSBT.F Stock Overview

A biopharmaceutical company, engages in the commercialization and development for tissue repair and bone regeneration in the United States, the European Union, and internationally. More details

CSBT.F fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Kuros Biosciences AG Competitors

Price History & Performance

Summary of share price highs, lows and changes for Kuros Biosciences
Historical stock prices
Current Share PriceCHF 22.57
52 Week HighCHF 36.10
52 Week LowCHF 3.85
Beta0.78
1 Month Change-11.59%
3 Month Change2.59%
1 Year Change431.06%
3 Year Changen/a
5 Year Change6,315.58%
Change since IPO7,180.65%

Recent News & Updates

Recent updates

Shareholder Returns

CSBT.FUS BiotechsUS Market
7D0%-3.3%-2.2%
1Y431.1%-1.9%23.9%

Return vs Industry: CSBT.F exceeded the US Biotechs industry which returned -1.9% over the past year.

Return vs Market: CSBT.F exceeded the US Market which returned 23.9% over the past year.

Price Volatility

Is CSBT.F's price volatile compared to industry and market?
CSBT.F volatility
CSBT.F Average Weekly Movementn/a
Biotechs Industry Average Movement10.7%
Market Average Movement6.3%
10% most volatile stocks in US Market17.0%
10% least volatile stocks in US Market3.1%

Stable Share Price: Data is not available.

Volatility Over Time: Insufficient data to determine CSBT.F's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
2016106Chris Fairwww.kuros.ch

Kuros Biosciences AG, a biopharmaceutical company, engages in the commercialization and development for tissue repair and bone regeneration in the United States, the European Union, and internationally. It operates through three segments: Medical Devices, Pharmaceuticals, and Legacy Portfolio. The company offers MagnetOs Granules, an original advanced bone graft based on the submicron needle-shaped NeedleGrip surface technology; MagnetOs Putty, a mold use to fill bony voids for a predictable fusion; MagnetOs Easypack Putty, a ready-to-use mold to be implanted in any intervertebral disc space or posterolateral spine level; and Magnetos Flex Matrix, an open matrix bone graft.

Kuros Biosciences AG Fundamentals Summary

How do Kuros Biosciences's earnings and revenue compare to its market cap?
CSBT.F fundamental statistics
Market capUS$844.66m
Earnings (TTM)-US$9.89m
Revenue (TTM)US$58.47m

14.4x

P/S Ratio

-85.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CSBT.F income statement (TTM)
RevenueCHF 52.54m
Cost of RevenueCHF 6.43m
Gross ProfitCHF 46.11m
Other ExpensesCHF 55.00m
Earnings-CHF 8.89m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.24
Gross Margin87.77%
Net Profit Margin-16.91%
Debt/Equity Ratio0%

How did CSBT.F perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 02:37
End of Day Share Price 2024/12/11 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Kuros Biosciences AG is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Laura Pfeifer-RossiBank am Bellevue
Olav ZilianMirabaud Securities Limited
Dylan van HaaftenNIBC Bank N.V.